

Terence J Colgan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11279901/publications.pdf>

Version: 2024-02-01

63
papers

3,073
citations

249298

26
h-index

175968

55
g-index

66
all docs

66
docs citations

66
times ranked

3013
citing authors

#	ARTICLE	IF	CITATIONS
1	Does Ki-67 Have a Role in the Diagnosis of Placental Molar Disease?. International Journal of Gynecological Pathology, 2020, 39, 1-7.	0.9	3
2	Trends in the US and Canadian Pathologist Workforces From 2007 to 2017. JAMA Network Open, 2019, 2, e194337.	2.8	174
3	BRCA1 Mutation Status and Follicular Fluid Exposure Alters NF κ B Signaling and ISGylation in Human Fallopian Tube Epithelial Cells. Neoplasia, 2018, 20, 697-709.	2.3	8
4	Competing Interests and HPV-Based Primary Screening. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 325.	0.3	2
5	DNA Genotyping of Suspected Partial Hydatidiform Moles Detects Clinically Significant Aneuploidy. International Journal of Gynecological Pathology, 2017, 36, 217-221.	0.9	12
6	Molecular Diagnosis of Placental Hydatidiform Mole: Innovation and Outcomes. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 1049-1052.	0.3	4
7	Gynecologic cytology in <i>Cancer Cytopathology</i>: 20 years of massive change. Cancer Cytopathology, 2016, 124, 535-537.	1.4	1
8	A Reappraisal of the Incidence of Placental Hydatidiform Mole Using Selective Molecular Genotyping. International Journal of Gynecological Cancer, 2016, 26, 1345-1350.	1.2	6
9	Placental Molar Disease. International Journal of Gynecological Pathology, 2015, 34, 411-418.	0.9	8
10	Prognostic significance of a positive axillary lymph node fine-needle aspirate in patients with invasive breast carcinoma. Cancer Cytopathology, 2014, 122, 138-144.	1.4	4
11	Papillary Syncytial Metaplasia of Fallopian Tube Endometriosis: A Potential Pitfall in the Diagnosis of Serous Tubal Intraepithelial Carcinoma. Archives of Pathology and Laboratory Medicine, 2013, 137, 126-129.	1.2	3
12	Superficially Invasive Squamous Cell Carcinoma of the Uterine Cervix. , 2013, 18, 183-189.		2
13	A validation study of the FocalPoint GS imaging system for gynecologic cytology screening. Cancer Cytopathology, 2013, 121, 189-196.	1.4	15
14	The Practice of Pathology in Canada: Decreasing Pathologist Supply and Uncertain Outcomes. Archives of Pathology and Laboratory Medicine, 2012, 136, 90-94.	1.2	9
15	Identification of Novel Molecular Targets for Endometrial Cancer Using a Drill-Down LC-MS/MS Approach with iTRAQ. PLoS ONE, 2011, 6, e16352.	1.1	40
16	Recent Developments in Defining Microinvasive and Early Invasive Carcinoma of the Uterine Cervix. Journal of Lower Genital Tract Disease, 2011, 15, 146-157.	0.9	26
17	The evolving role of axillary lymph node fine-needle aspiration in the management of carcinoma of the breast. Cancer Cytopathology, 2011, 119, 328-334.	1.4	28
18	Familial Cancer and Prophylactic Surgery. , 2011, , 277-288.		0

#	ARTICLE	IF	CITATIONS
19	Fallopian Tube and Peritoneum. , 2011, , 267-275.		1
20	mTRAQ-based quantification of potential endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded tissues. <i>Proteomics</i> , 2010, 10, 3108-3116.	1.3	59
21	Absolute Quantification of Potential Cancer Markers in Clinical Tissue Homogenates Using Multiple Reaction Monitoring on a Hybrid Triple Quadrupole/Linear Ion Trap Tandem Mass Spectrometer. <i>Analytical Chemistry</i> , 2009, 81, 3462-3470.	3.2	78
22	Multiple Reaction Monitoring of mTRAQ-Labeled Peptides Enables Absolute Quantification of Endogenous Levels of a Potential Cancer Marker in Cancerous and Normal Endometrial Tissues. <i>Journal of Proteome Research</i> , 2008, 7, 3525-3534.	1.8	166
23	Endometrial Carcinoma Biomarker Discovery and Verification Using Differentially Tagged Clinical Samples with Multidimensional Liquid Chromatography and Tandem Mass Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1170-1182.	2.5	93
24	Vanishing Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 271-277.	0.9	10
25	Verification of Endometrial Tissue Biomarkers Previously Discovered Using Mass Spectrometry-Based Proteomics by Means of Immunohistochemistry in a Tissue Microarray Format. <i>Journal of Proteome Research</i> , 2007, 6, 2648-2655.	1.8	32
26	Identification of Candidate Biomarker Proteins Released by Human Endometrial and Cervical Cancer Cells Using Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry. <i>Journal of Proteome Research</i> , 2007, 6, 2615-2622.	1.8	25
27	Laparoscopic Ultrasound-Guided Radiofrequency Ablation of Uterine Fibroids. <i>CardioVascular and Interventional Radiology</i> , 2006, 29, 694-698.	0.9	26
28	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. <i>Gynecologic Oncology</i> , 2006, 100, 58-64.	0.6	349
29	Hyperchromatic Crowded Groups in Cervical Cytology—Differing Appearances and Interpretations in Conventional and ThinPrep Preparations: A Study From the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 332-336.	1.2	23
30	Robustness of Validation Criteria in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1119-1122.	1.2	12
31	The Significance of Certification in Liquid-Based Cytology and Performance in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytopathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1269-1272.	1.2	2
32	Proteomic analysis of the proliferative and secretory phases of the human endometrium: Protein identification and differential protein expression. <i>Proteomics</i> , 2005, 5, 270-281.	1.3	88
33	A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: Calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma. <i>Proteomics</i> , 2005, 5, 1953-1966.	1.3	33
34	Direct analysis of laser capture microdissected endometrial carcinoma and epithelium by matrix-assisted laser desorption/ionization mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 2762-2766.	0.7	25
35	Search for Cancer Markers from Endometrial Tissues Using Differentially Labeled Tags iTRAQ and cICAT with Multidimensional Liquid Chromatography and Tandem Mass Spectrometry. <i>Journal of Proteome Research</i> , 2005, 4, 377-386.	1.8	356
36	Measuring the Significance of Field Validation in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology: How Good Are the Experts?. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, 609-613.	1.2	22

#	ARTICLE	IF	CITATIONS
37	Measuring the Significance of Participant Evaluation of Acceptability of Cases in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Archives of Pathology and Laboratory Medicine, 2005, 129, 1093-1096.	1.2	4
38	Results of the implementation of liquid-based cytology-SurePath in the Ontario screening program. Cancer, 2004, 102, 362-367.	2.0	20
39	Protein Expression Profiling of Endometrial Malignancies Reveals a New Tumor Marker:Â Chaperonin 10. Journal of Proteome Research, 2004, 3, 636-643.	1.8	59
40	Long-Term Surveillance Is Required for All Women Treated for Cervical Adenocarcinoma In Situ. Journal of Lower Genital Tract Disease, 2004, 8, 125-131.	0.9	16
41	Comparison of Performance of Conventional and ThinPrep Gynecologic Preparations in the College of American Pathologists Gynecologic Cytology Program. Archives of Pathology and Laboratory Medicine, 2004, 128, 17-22.	1.2	50
42	Women Harboring BRCA1/2 Germline Mutations are at Risk for Breast and Female Adnexal Carcinoma. International Journal of Gynecological Pathology, 2003, 22, 315.	0.9	12
43	Challenges in the Early Diagnosis and Staging of Fallopian-Tube Carcinomas Associated with BRCA Mutations. International Journal of Gynecological Pathology, 2003, 22, 109-120.	0.9	54
44	Pathologic Features of Uteri and Leiomyomas Following Uterine Artery Embolization for Leiomyomas. American Journal of Surgical Pathology, 2003, 27, 167-177.	2.1	98
45	Precision in Gynecologic Cytologic Interpretation: A Study From the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Archives of Pathology and Laboratory Medicine, 2003, 127, 1413-1420.	1.2	43
46	Costs of prophylactic resection. Cmaj, 2003, 169, 105.	0.9	0
47	Screening for cervical disease in mature women. Cancer, 2002, 96, 195-203.	2.0	21
48	Peritoneal Lavage Cytology: An Assessment of Its Value during Prophylactic Oophorectomy. Gynecologic Oncology, 2002, 85, 397-403.	0.6	80
49	Occult Carcinoma in Prophylactic Oophorectomy Specimens. American Journal of Surgical Pathology, 2001, 25, 1283-1289.	2.1	337
50	The annual Papanicolaou test. Cancer, 2001, 93, 81-85.	2.0	10
51	Reparative Changes and the False-Positive/False-Negative Papanicolaou Test. Archives of Pathology and Laboratory Medicine, 2001, 125, 134-140.	1.2	36
52	Litigation and the Canadian pap test: Perspectives from a single-payer system. , 2000, 22, 207-210.		0
53	Detection of high grade squamous intraepithelial lesions and tumors using the AutoPap system. Cancer, 1999, 87, 354-358.	2.0	36
54	AutoPap System Detection of Infections and Benign Cellular Changes: Results From Primary Screener Clinical Trials. , 1999, 21, 355-358.		12

#	ARTICLE	IF	CITATIONS
55	Post-Hysteroscopic Ablation Reaction. International Journal of Gynecological Pathology, 1999, 18, 325-331.	0.9	27
56	The AutoPap System for Primary Screening in Cervical Cytology. Acta Cytologica, 1998, 42, 214-220.	0.7	119
57	AutoPap 300 QC System Scoring of Cervical Smears Without "Epithelial Cell Abnormalities": Acta Cytologica, 1997, 41, 45-49.	0.7	6
58	Enhancing the Performance of the AutoPap 300 QC System with Optimal Staining and Presentation of Cervical Smears. Acta Cytologica, 1997, 41, 50-55.	0.7	6
59	The cytopathologist: Workload, regulations, and the forgotten professional. Diagnostic Cytopathology, 1997, 17, 313-314.	0.5	2
60	The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Human Pathology, 1993, 24, 1073-1077.	1.1	76
61	COLPOSCOPY OF ADENOCARCINOMA IN SITU AND INVASIVE ADENOCARCINOMA OF THE CERVIX. Obstetrics and Gynecology Clinics of North America, 1993, 20, 111-122.	0.7	30
62	Osteogenic Sarcoma with Epithelial Differentiation. Ultrastructural Pathology, 1992, 16, 463-474.	0.4	18
63	The anatomic distribution of cervical adenocarcinoma in situ: Implications for treatment. American Journal of Obstetrics and Gynecology, 1987, 157, 21-25.	0.7	144